Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 212896

1.

Expressions of KAI1 and E-cadherin in nonsmall cell lung cancer and their correlation with vasculogenic mimicry.

Ci H, Xu Z, Xu J, Wang Y, Wu S.

Medicine (Baltimore). 2018 Oct;97(40):e12293. doi: 10.1097/MD.0000000000012293.

2.

Alveolar architectures preserved in cancer tissues may be potential pitfalls for diagnosis and histological subtyping of lung cancer: Three case reports.

Fan X, Zhang X, Wang E, Fan C.

Medicine (Baltimore). 2018 Sep;97(39):e12613. doi: 10.1097/MD.0000000000012613.

3.

Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies.

Liu J, Hu Z, Feng Y, Zeng S, Zhong M.

Medicine (Baltimore). 2018 Sep;97(39):e12603. doi: 10.1097/MD.0000000000012603.

4.

Effects of postoperative non-steroidal anti-inflammatory drugs on long-term survival and recurrence of patients with non-small cell lung cancer.

Jiang W, Wang L, Zhang J, Shen H, Dong W, Zhang T, Li X, Wang K, Du J.

Medicine (Baltimore). 2018 Sep;97(39):e12442. doi: 10.1097/MD.0000000000012442.

5.

Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.

Thangarajah F, Vogel C, Pahmeyer C, Eichler C, Holtschmidt J, Ratiu D, Mallmann P, Malter W.

Anticancer Res. 2018 Oct;38(10):6023-6026. doi: 10.21873/anticanres.12952.

PMID:
30275235
6.

Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.

Yoon N, Kim J, Maeng LS, Ahn JH, Park ES.

Anticancer Res. 2018 Oct;38(10):6003-6008. doi: 10.21873/anticanres.12949.

PMID:
30275232
7.

Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer.

Wada K, Kishi N, Kanayama N, Hirata T, Morimoto M, Konishi K, Imamura F, Teshima T, Ogawa K.

Anticancer Res. 2018 Oct;38(10):5951-5958. doi: 10.21873/anticanres.12941.

PMID:
30275224
8.

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.

Takamori S, Takada K, Azuma K, Jogo Y, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Toyokawa G, Hirai F, Tagawa T, Okamoto I, Nakanishi Y, Kawahara A, Akiba J, Oda Y, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5903-5907. doi: 10.21873/anticanres.12934.

PMID:
30275217
9.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

PMID:
30275216
10.

The Contribution of MMP-7 Promoter Polymorphisms to Taiwan Lung Cancer Susceptibility.

Chen GL, Shen TC, Chang WS, Tsai CW, Li HT, Chuang CL, Lai YL, Yueh TC, Hsia TC, Wang SC, Bau DT.

Anticancer Res. 2018 Oct;38(10):5671-5677. doi: 10.21873/anticanres.12903.

PMID:
30275186
11.

Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.

Youssef O, Knuuttila A, Piirilä P, Böhling T, Sarhadi V, Knuutila S.

Anticancer Res. 2018 Oct;38(10):5627-5634. doi: 10.21873/anticanres.12897.

PMID:
30275180
12.

Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.

Freeman J, Crowley PD, Foley AG, Gallagher HC, Iwasaki M, Ma D, Buggy DJ.

Anticancer Res. 2018 Oct;38(10):5599-5606. doi: 10.21873/anticanres.12894.

PMID:
30275177
13.

[Association between Arsenic Intake and Cancer-From the Viewpoint of Epidemiological Study].

Sawada N.

Nihon Eiseigaku Zasshi. 2018;73(3):265-268. doi: 10.1265/jjh.73.265. Review. Japanese.

14.

Lung Cancer Screening in the Community Setting: Challenges for Adoption.

Randhawa S, Drizin G, Kane T, Song GY, Reilly T, Jarrar D.

Am Surg. 2018 Sep 1;84(9):1415-1421.

PMID:
30268168
15.

Atezolizumab Treatment of Nonsquamous NSCLC.

Ashraf N.

N Engl J Med. 2018 Sep 20;379(12):1187-8. doi: 10.1056/NEJMc1809195. No abstract available.

PMID:
30260157
16.

Atezolizumab Treatment of Nonsquamous NSCLC.

Mountzios G, Calles A, Addeo A.

N Engl J Med. 2018 Sep 20;379(12):1187. doi: 10.1056/NEJMc1809195. No abstract available.

PMID:
30260156
17.

Complementary and Integrative Medicine in Lung Cancer: Questions and Challenges.

Frenkel M, Slater R, Sapire K, Sierpina V.

J Altern Complement Med. 2018 Sep/Oct;24(9-10):862-871. doi: 10.1089/acm.2018.0175. Review.

PMID:
30247955
18.

Score for lung adenocarcinoma in China with EGFR mutation of exon 19: Combination of clinical and radiological characteristics analysis.

Shi Z, Zheng X, Shi R, Song C, Yang R, Zhang Q, Wang X, Lu J, Yu Y, Jiang T.

Medicine (Baltimore). 2018 Sep;97(38):e12537. doi: 10.1097/MD.0000000000012537.

19.

Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer.

Deng T, Zhang J, Meng Y, Zhou Y, Li W.

Medicine (Baltimore). 2018 Sep;97(38):e12524. doi: 10.1097/MD.0000000000012524. Review.

20.

Hepatic toxicity following actinomycin D chemotherapy in treatment of familial gestational trophoblastic neoplasia: A case report.

Mu X, Yin R, Wang D, Song L, Ma Y, Zhao X, Li Q.

Medicine (Baltimore). 2018 Sep;97(38):e12424. doi: 10.1097/MD.0000000000012424.

Supplemental Content

Loading ...
Support Center